Wave Life Sciences, Inc. (WVE)
Nasdaq · Healthcare · Biotechnology
$3.75−0.79%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $739M
- 52-week range
- $3.56 – $21.73
- 52-week change
- −47.65%
- EPS (trailing)
- −$1.08
- Analyst rating
- 1.3 Strong buy
- Next earnings
- Nov 9, 2026
Fiscal year to Dec 2025
- Revenue
- $42.7M (−60.55%)
- Net income
- −$204M
- Operating margin
- −504.1%
- Diluted EPS
- −$1.21
- Free cash flow
- −$188M
From the company’s annual report on SEC EDGAR.
About Wave Life Sciences, Inc.
Wave Life Sciences, Inc., a clinical-stage biotechnology company, focuses on unlocking the potential of ribonucleic acid (RNA) medicines to transform human health. Its RNA medicines platform, PRISM, combines RNA medicine modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat rare and common disorders. Its pipeline focuses on obesity (WVE-007), alpha-1 antitrypsin deficiency (AATD) (WVE-006), and PNPLA3 I148M liver disease (WVE-008) programs; and clinical programs for Duchenne muscular dystrophy and Huntington's disease, as well as various preclinical programs utilizing its RNA medicines platform. Wave Life Sciences, Inc. was founded in 2012 and is headquartered in Cambridge, Massachusetts.
Headquarters: Cambridge, United States · 317 employees · wavelifesciences.com